Nivolumab: promising survival signal coupled with limited toxicity raises expectations

J Clin Oncol. 2014 Apr 1;32(10):986-8. doi: 10.1200/JCO.2013.54.5996. Epub 2014 Mar 3.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Nivolumab
  • Skin Neoplasms / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab